Patent Application
20140178329
The disclosure relates to biotechnology generally and more specifically to novel variants of APRIL, which modulate the signaling toward specific receptor agonist activity, and nucleic acids encoding these variant proteins. It further relates to the use of these novel proteins in the treatment of APRIL-associated disorders, in particular, pathologies of the immune system and oncological disorders.
A proliferation inducing ligand (APRIL) is a member of the TNF ligand superfamily originally described as a tumor-promoting factor.(1) Physiologically, it plays a prominent role in humoral immunity, in particular, by driving antibody class-switch toward IgG and IgA,(2, 3) and by promoting survival of plasma cells.(4) APRIL has also been identified as a pro-survival factor for several B cell malignancies, possibly via the activation of transcription factor NF-κB (reviewed in reference (5)). APRIL is also thought to promote tumor formation in a number of solid malignancies, either indirectly via infiltrating cells or directly via autocrine stimulation of the tumor itself.(1, 6, 7) In line with these results, we recently identified a clear role for APRIL in supporting tumorigenesis in the gastrointestinal tract.(8)
As most TNF ligand factors, APRIL is synthesized as a precursor protein, which is further processed into a mature form. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase, an enzyme that cleaves the full length APRIL protein (250 amino acids) between amino acids 104-105 (numbering according to UniprotKB/SwissProt entry 075888) and releases the soluble, extracellular receptor-binding region (amino acids 105-250) from the propeptide region (amino acids 1-104).(39) A membrane-bound form of APRIL is generated by an alternative splicing event in which a fusion is generated between the extracellular portion of APRIL (amino acids 86-250) and the transmembrane and intracellular portion of TNF-related weak inducer of apoptosis (TWEAK) (amino acids 1-165)—the end product named TWE-PRIL. However, the biological relevance and expression of TWE-PRIL is little understood.(40, 41, 42)
APRIL binds two different receptors of the TNF receptor superfamily: B cell maturation antigen (BCMA), and transmembrane activator and cyclophilin ligand interactor (TACI), which are also bound by its homolog B cell-activating factor (BAFF).(9-12) In addition, APRIL binds to heparan sulphate proteoglycans (HSPGs), which appear to play a predominantly structural role by enabling APRIL cross-linking,(13, 14) although a distinct signaling role in different contexts cannot be eliminated. In addition to APRIL, TACI can also bind to HSPGs, which is suggested to lead to its activation.(15) All these potential binding partners make it difficult to unravel APRIL signaling in a given context, and to assess the individual contributions of TACI and BCMA. Therefore, it is not surprising that little is known about the individual signaling pathways activated in response to signals via each of the APRIL receptors, or precisely how these are separated in terms of the formation of distinct intracellular complexes and recruitment of signaling adaptors. Much of what is currently known with regard to activation of transcription factors and recruitment of internal adaptors, such as TNF-receptor associated factors (TRAFs), has been carried out using transfection studies(16, 17) or RNAi-mediated knock-down studies,(18) which pose possible problems associated with over-expression or simultaneous removal of multiple interactions, respectively. A need exists in the art to develop APRIL variants that can interfere with distinct intracellular signaling processes.
Thus, it was an aim hereof to develop such APRIL variants with receptor-interaction domains that are modified, such that each domain has either i) significantly reduced affinity and concomitant reduction in signaling capacity for one or more cognate receptors, ii) significantly enhanced affinity and concomitant increase in signaling capacity for one of its cognate receptors, or iii) a combination of i) and ii). More specifically, variants of the soluble, extracellular region of APRIL including the receptor-interaction domain modified as described herein have been produced and used.
In the disclosure, generated were variant forms of the APRIL protein and tested their ability to bind either BCMA or TACI. Six mutants (or variants, which is here used as an equivalent term) were of particular interest: APRIL-R206E, APRIL-R206M, APRIL-T175D, and APRIL-D205Y, which showed clear specificity toward both human and mouse BCMA, and APRIL-D132F and APRIL-D132Y, which showed considerable selectivity for TACI. Following initial ELISAs using immobilized receptors, we further confirmed the binding characteristics in the context of cell-based assays, using either transfected cells in which receptors were over-expressed, or endogenously expressing BCMA or TACI cell species. Finally, we used these APRIL variants in a B cell assay to show distinct roles for TACI and BCMA in B cell function.
Accordingly, provided are variants of the extracellular domain of APRIL ligand proteins that modulate the bioactivity of APRIL receptors. Provided are variant APRIL proteins that comprise an amino acid sequence (“peptide”) that has one modification as compared to the naturally occurring APRIL protein sequence.
In a specific aspect, provided is an APRIL variant polypeptide comprising a polypeptide sequence selected from the list consisting of SEQ ID NOS:2, 4, 6, 8, 10 or 12, or a fragment corresponding to amino acids 104-250 or 105-250 in SEQ ID NOS:2, 4, 6, 8, 10 or 12.
In yet another aspect, provided is a recombinant nucleic acid encoding a variant APRIL polypeptide hereof.
In a particular embodiment, a recombinant nucleic acid encoding a fragment of SEQ ID NOS:2, 4, 6, 8, 10 or 12 corresponds with a nucleic acid sequence starting at nucleotide 310 or 313 and ending at nucleotide 750 in SEQ ID NOS:1, 3, 5, 7, 9 or 11.
In the disclosure, the terms “polypeptide” and “protein” are equivalent terms with the same meaning.
In yet another aspect, provided is an expression vector comprising a recombinant nucleic acid hereof.
In yet another aspect, provided is a host cell comprising a recombinant nucleic acid hereof.
In yet another aspect, provided is a host cell comprising an expression vector hereof.
In yet another aspect, provided is a method for producing a variant APRIL polypeptide hereof comprising culturing a recombinant host cell under conditions suitable for expression of a nucleic acid hereof.
In yet another aspect, an APRIL variant polypeptide hereof is used for the treatment of an APRIL-associated disorder.
In yet another aspect, provided is a pharmaceutical composition comprising an APRIL variant polypeptide hereof and a pharmaceutically acceptable carrier.
In yet another aspect, provided is a pharmaceutical composition for the treatment of an APRIL-associated disorder.
In yet another aspect, provided are cell lines and animal models comprising APRIL variant nucleotide sequences hereof.
In yet another embodiment, provided is the use of the APRIL polypeptide variants hereof for in vivo or in vitro or ex vivo treatment applications.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
The disclosure will be described with respect to particular embodiments and with reference to certain drawings but the disclosure is not limited thereto, but only by the claims. Any reference signs in the claims shall not be construed as limiting the scope. The drawings described are only schematic and are non-limiting. Where the term “comprising” is used in the present description and claims, it does not exclude other elements or steps. Where an indefinite or definite article is used when referring to a singular noun, e.g., “a,” “an,” or “the,” this includes a plural of that noun unless something else is specifically stated. Furthermore, the terms “first,” “second,” “third,” and the like, in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments hereof described herein are capable of operation in other sequences than described or illustrated herein.
The following terms or definitions are provided solely to aid in the understanding hereof. Unless specifically defined herein, all terms used herein have the same meaning as they would to one skilled in the art. Practitioners are particularly directed to Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Press, Plainsview, N.Y. (2012); and Ausubel et al., Current Protocols in Molecular Biology (Supplement 100), John Wiley & Sons, New York (2012), for definitions and terms of the art. The definitions provided herein should not be construed to have a scope less than understood by a person of ordinary skill in the art.
The proliferation-inducing ligand (APRIL) (also known as TRDL-1 alpha, TALL-2, TNFSF13) and its closest homologue, BAFF (also known as B-cell Activation Factor, BLyS, TALL-1, THANK, zTNF4 and TNFSF13B), are members of the TNF super family (TNFSF) of proteins. The prototype of the family, Tumor Necrosis Factor Alpha (TNFA), originally discovered for its in vivo effect causing tumors to regress, is a key mediator of inflammation. BAFF and APRIL proteins participate in a variety of cellular and intracellular signaling processes, and are synthesized as type 2 membrane proteins that fold into conserved beta-sheet structures and can be cleaved intracellularly or from the membrane to be secreted as soluble forms. APRIL is also implicated in several cancers as a pro-survival factor. APRIL binds two different TNF receptors: B cell maturation antigen (BCMA), and transmembrane activator and cyclophilin ligand interactor (TACI), and also interacts independently with heparan sulfate proteoglycans (HSPGs). As APRIL shares binding of the TNF receptors with B cell activation factor (BAFF), separating the precise signaling pathways activated by either ligand in a given context has proven quite difficult. The human APRIL DNA Genbank sequence record is AF046888. Residue numbering of the variants is based on the human APRIL protein sequence (also depicted in SEQ ID NO:14) as described in the Expasy Uniprot record (O75888).
SEQ ID NO:1 depicts the nucleotide sequence of the full-length APRIL-R206E variant.
SEQ ID NO:2 depicts the amino acid sequence of the full-length APRIL-R206E variant.
SEQ ID NO:3 depicts the nucleotide sequence of the full-length APRIL-D132F variant.
SEQ ID NO:4 depicts the amino acid sequence of the full-length APRIL-D132F variant.
SEQ ID NO:5 depicts the nucleotide sequence of the full-length APRIL-D132Y variant.
SEQ ID NO:6 depicts the amino acid sequence of the full-length APRIL-D132Y variant.
SEQ ID NO:7 depicts the nucleotide sequence of the full-length APRIL-R206M variant.
SEQ ID NO:8 depicts the amino acid sequence of the full-length APRIL-R206M variant.
SEQ ID NO:9 depicts the nucleotide sequence of the full-length APRIL-D205Y variant.
SEQ ID NO:10 depicts the amino acid sequence of the full-length APRIL-D205Y variant.
SEQ ID NO:11 depicts the nucleotide sequence of the full-length APRIL-T175D variant.
SEQ ID NO:12 depicts the amino acid sequence of the full-length APRIL-T175D variant.
SEQ ID NO:13 depicts the nucleotide sequence of the full-length wild-type APRIL
SEQ ID NO:14 depicts the amino acid sequence of the full-length wild-type APRIL.
Four BCMA-specific variants of APRIL were successfully generated: APRIL-R206E, APRIL-R206M, APRIL-T175D and APRIL-D205Y and two TACI-selective variants: D132F and D132Y. These six different APRIL variants show selective activity toward their receptors in several in vitro assays. Moreover, in the disclosure, we show through these APRIL variants that BCMA and TACI have a distinct role in APRIL-induced B cell stimulation.
In certain embodiments, a mutant APRIL nucleic acid encodes a mutant APRIL protein. As will be appreciated by those in the art, due to the degeneracy of the genetic code, an extremely large number of nucleic acids may be made, all of which encode a specific variant APRIL protein of the disclosure. Thus, having the six particular amino acid sequences of the variants hereof, those skilled in the art could make any number of different nucleic acids, by simply modifying the sequence of one or more codons in a way that does not change the amino acid sequence of the variant APRIL proteins.
In certain embodiments, the variant APRIL proteins and nucleic acids are recombinant. As used herein, “nucleic acid” may refer to either DNA or RNA, or molecules that contain both desoxy- and ribonucleotides. The nucleic acids include genomic DNA, cDNA and oligonucleotides including sense and anti-sense nucleic acids. Such nucleic acids may also contain modifications in the ribose-phosphate backbone to increase stability and half-life of such molecules in physiological environments. The nucleic acid may be double-stranded, single-stranded, or contain portions of both double-stranded or single-stranded sequence. As will be appreciated by those in the art, the depiction of a single strand (“Watson”) also defines the sequence of the other strand (“Crick”). By the term “recombinant nucleic acid” herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid by endonucleases or through, for example, gene synthesis, in a form not normally found in nature. Thus, an isolated variant APRIL nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes hereof. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., using the in vivo cellular machinery of the host cell rather than in vitro manipulations, however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes hereof. A “recombinant protein” is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid. A recombinant protein is distinguished from naturally occurring protein by at least one or more characteristics. For example, the protein may be isolated or purified away from some or all of the proteins and compounds with which it is normally associated in its wild-type host, and thus may be substantially pure. A substantially pure protein comprises at least about 75% by weight of the total protein, with at least about 80% being preferred, and at least about 90% being particularly preferred. The definition includes the production of a variant APRIL protein from one organism in a different organism or host cell. Alternatively, the protein may be made at a significantly higher concentration than is normally seen, through the use of an inducible promoter or high expression promoter, such that the protein is made at increased concentration levels.
In certain embodiments, variant APRIL proteins may be prepared by in vitro synthesis using established techniques (e.g., chemical synthesis; see, for example, Wilken et al., Curr. Opin. Biotechnol. 9:412-26 (1998)).
Using the nucleic acids hereof, which encode a variant APRIL protein, a variety of expression vectors can be prepared. The expression vectors may be either self-replicating extrachromosomal vectors or vectors that integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acids operably linked to the nucleic acid encoding the variant APRIL protein. The term “control sequences” refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
A nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a pre-sequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a pre-protein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. In general, the transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In certain embodiments, the regulatory sequences include a promoter and transcriptional start and stop sequences.
Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the disclosure. In certain embodiments, the promoters are strong promoters, allowing high expression in cells, particularly mammalian cells, such as the CMV promoter, particularly in combination with a Tet regulatory element.
In addition, the expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example, in mammalian or insect cells for expression and in a prokaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences that flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs and methods for integrating vectors are well known in the art.
In addition, in certain embodiments, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.
In certain embodiments, the expression vector comprises the components described above and a gene encoding a variant APRIL protein. As will be appreciated by those in the art, all combinations are possible and accordingly, as used herein, the combination of components, comprised by one or more vectors, which may be retroviral or not, is referred to herein as a “vector composition.”
In particular embodiments, the variant APRIL proteins of the disclosure are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a variant APRIL protein, under the appropriate conditions to induce or cause expression of the variant APRIL protein. The conditions appropriate for variant APRIL protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are Drosophila melanogaster cells, Saccharomyces cerevisiae and other yeasts, E. coli, Bacillus subtilis, SF9 cells, 293 cells, CHO, COS, Pichia pastoris and the like.
In certain embodiments, the variant APRIL proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral systems. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3′) transcription of a coding sequence for the protein into mRNA. A promoter will have a transcription-initiating region, which is usually placed proximal to the 5′ end of the coding sequence, and a TATA box located 25-30 base pairs upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element (enhancer element), typically located within 100 to 200 base pairs upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter.
In another embodiment, provided is a cell line (such as a mammalian cell line) comprising a nucleotide sequence encoding a variant APRIL polypeptide hereof. In another particular embodiment, provided is a transgenic non-human animal (e.g., a mouse or a rat) comprising a nucleotide sequence encoding a variant APRIL polypeptide hereof. In a particular embodiment (part of), one or both of the WT alleles in human or other mammalian (e.g., stem) cells can be replaced with a variant encoding sequence using genome/gene-editing technology (zinc finger nucleases, mega-nucleases, TALEN, etc.).
In another particular embodiment, the variant APRIL proteins are used for the manufacture of a medicament to treat APRIL-associated diseases.
In certain embodiments, the variant APRIL proteins are used to treat APRIL-associated diseases.
Variant APRIL proteins hereof can be expressed as chimeric proteins, fused to other functional protein domains in order to further enhance it therapeutic efficacy. For example, a fusion with a trimerizing domain can enhance the stability, reduce clearance and improve pharmacokinetics and half-life of APRIL variant proteins. Similarly, fusion with a serum albumin binding domain can reduce clearance and improve pharmacokinetic parameters such as half-life. Fusion with a toxin can be used to selectively target and destroy TACI or BCMA-expressing cells. Variant APRIL proteins might also be expressed as fusions with a domain that selectively targets a specific subset of cells, for example, cancer cells.
Variant APRIL proteins or variant APRIL chimeric proteins can also be modified by pegylation or particular forms of glycosylation in order to improve half-life and stability or reduce immunogenicity. As will be appreciated, modifications such as pegylation will be achieved by chemical means, whereas glycosylation can be achieved chemically or biologically.
The term “APRIL-associated diseases” comprises congestive heart failure (CHF), skin diseases (e.g., acne, eczema), myocarditis and other conditions of the myocardium, systemic lupus erythematosus, diabetes, spondylopathies, multiple myeloma, breast cancer, lung cancer, kidney cancer and rectal cancer; bone metastasis, ankylosing spondylitis, transplant rejection, hematologic neoplasias and neoplastic-like conditions, for example, Hodgkin's lymphoma; non-Hodgkin's lymphomas (Burkitt's lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, hairy cell leukemia and lymphoplasmacytic leukemia), tumors of lymphocyte precursor cells, including B-cell acute lymphoblastic leukemia/lymphoma, and T-cell acute lymphoblastic leukemia/lymphoma, thymoma, tumors of the mature T and NK cells, including peripheral T-cell leukemias, adult T-cell leukemia/T-cell lymphomas and large granular lymphocytic leukemia, Langerhans cell histocytosis, myeloid neoplasias such as acute myelogenous leukemias, including AML with maturation, AML without differentiation, acute promyelocytic leukemia, acute myelomonocytic leukemia, and acute monocytic leukemias, myelodysplastic syndromes, and chronic myeloproliferative disorders, including chronic myelogenous leukemia, tumors of the central nervous system, e.g., brain tumors (glioma, neuroblastoma, astrocytoma, medulloblastoma, ependymoma, and retinoblastoma), solid tumors (nasopharyngeal cancer, basal cell carcinoma, pancreatic cancer, cancer of the bile duct, Kaposi's sarcoma, testicular cancer, uterine, vaginal or cervical cancers, ovarian cancer, primary liver cancer or endometrial cancer, and tumors of the vascular system (angiosarcoma and hemangiopericytoma), rheumatoid arthritis, inflammatory bowel diseases (IBD), sepsis and septic shock, Crohn's Disease, psoriasis, schleraderma, graft versus host disease (GVHD), allogenic islet graft rejection, hematologic malignancies, such as multiple myeloma (MM), myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML), cancer and the inflammation associated with tumors, peripheral nerve injury or demyelinating diseases.
The term “medicament to treat” relates to a composition comprising APRIL-variants as described above and a pharmaceutically acceptable carrier or excipient (both terms can be used interchangeably) to treat APRIL-associated diseases. Suitable carriers or excipients known to the skilled person are saline, Ringer's solution, dextrose solution, Hank's solution, fixed oils, ethyl oleate, 5% dextrose in saline, substances that enhance isotonicity and chemical stability, buffers and preservatives. Other suitable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids and amino acid copolymers (Gennaro (2000) Remington: The Science and Practice of Pharmacy 20th ed, ISBN: 0683306472). The “medicament” may be administered by any suitable method within the knowledge of the skilled person. The preferred route of administration is parenterally. In parental administration, the medicament hereof will be formulated in a unit dosage injectable form such as a solution, suspension or emulsion, in association with the pharmaceutically acceptable excipients as defined above. However, the dosage and mode of administration will depend on the individual and the particular indication. Generally, the medicament is administered so that the protein, polypeptide, or peptide of the disclosure is given at a dose between 1 μg/kg and 10 mg/kg, more preferably between 1 μg/kg and 5 mg/kg, most preferably between 1 and 100 μg/kg. Preferably, it is given as a bolus dose. Continuous infusion may also be used and includes continuous subcutaneous delivery via an osmotic minipump. If so, the medicament may be infused at a dose between 5 and 20 μg/kg/minute, more preferably between 7 and 15 μg/kg/minute. It is clear to the person skilled in the art that the use of a therapeutic composition comprising an APRIL-variant for the manufacture of a medicament to treat APRIL-associated diseases can be administered by any suitable means, including but not limited to, parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal administration. Parenteral infusions include intramuscular, intravenous, intra-arterial, intraperitoneal, or subcutaneous administration. In addition, the therapeutic composition is suitably administered by pulse infusion, particularly with declining doses of the APRIL-variant protein. Preferably, the therapeutic composition is given by injections, most preferably intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.
In a particular embodiment, the APRIL variants hereof can be used for in vivo treatment. The latter is discussed extensively hereinbefore.
In yet another particular embodiment, the APRIL variants hereof can be used for ex vivo treatment. The term “ex vivo treatment” implies that cells (e.g., orthologous cells or cells derived from a patient) are treated with an APRIL variant hereof for a certain amount of time and these treated cells are then subsequently brought back into a patient (e.g., through injection or other means of delivery). Applications for ex vivo therapy envisage the use of APRIL variants for expanding, selecting or differentiating blood cells (e.g., stem cells) that can be used for autologous transplantations or transfusions.
In a specific embodiment, nucleic acids comprising sequences encoding APRIL-variants are administered to treat APRIL-associated diseases by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment hereof, the nucleic acids produce APRIL-variants to treat APRIL-associated diseases. Any of the methods for gene therapy available in the art can be used according to the disclosure. Exemplary methods are described below. In case a nucleic acid sequence or a portion thereof capable of encoding an APRIL-variant is used for the manufacture of a medicament to treat APRIL-associated diseases, the medicament is preferably intended for delivery of the nucleic acid sequence into the cell, in a gene therapy treatment. A large number of delivery methods are well known to those of skill in the art. Preferably, the nucleic acids are administered for in vivo or ex vivo gene therapy uses. Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. Methods of non-viral delivery of nucleic acids include lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid: nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. A preferred method of non-viral delivery is via direct electroporation in muscle cells. Lipofection is described in, e.g., U.S. Pat. Nos. 5,049,386, 4,946,787, and 4,897,355, and lipofection reagents are sold commercially (e.g., TRANSFECTAM™ and LIPOFECTIN™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Flegner, WO 91/17424, WO 91/16024. Delivery can be to cells (ex vivo administration) or directly to target tissues such as muscle fibers (in vivo administration). The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal, 1995; Blaese et al., 1995; Behr, 1994; Remy et al., 1994; Gao and Huang, 1995; U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787). The use of RNA or DNA viral-based systems for the delivery of nucleic acids take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be administered directly to patients (in vivo) or they can be used to treat cells in vitro and the modified cells are administered to patients (ex vivo). Conventional viral-based systems for the delivery of nucleic acids include, amongst others, retroviral, lentiviral, adenoviral, adeno-associated and herpes simplex virus vectors for gene transfer. Viral vectors are currently the most efficient and versatile method of gene transfer in target cells and tissues. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long-term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues. In cases where transient expression of the nucleic acid is preferred, adenoviral-based systems, including replication-deficient adenoviral vectors, may be used. Adenoviral-based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system. Adeno-associated virus (“AAV”) vectors, including recombinant adeno-associated virus vectors, are also used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., U.S. Pat. No. 4,797,368; WO 93/24641; Kotin, 1994; The construction of recombinant AAV vectors is described in a number of publications, including U.S. Pat. No. 5,173,414; Hermonat & Muzyczka, 1984; Samulski et al., 1989). Gene therapy vectors can be delivered in vivo by administration to an individual patient, typically by systemic administration (e.g., intravenous, intraperitoneal, intratracheal, subdermal, or intracranial infusion) or topical application. In a particular embodiment, intramuscular administration is preferred. In another embodiment, envisaged is the use of a hydrodynamic gene therapeutic method. Hydrodynamic gene therapy is disclosed in U.S. Pat. No. 6,627,616 (Minis Corporation, Madison) and involves the intravascular delivery of non-viral nucleic acids encoding APRIL-variants, whereby the permeability of vessels is increased through, for example, the application of an increased pressure inside the vessel or through the co-administration of vessel permeability increasing compounds such as, for example, papaverine.
Alternatively, vectors can be delivered to cells ex vivo, such as cells explanted from an individual patient (e.g., lymphocytes, bone marrow aspirates, tissue biopsy, myoblasts) or universal donor hematopoietic stem cells, followed by re-implantation of the cells into a patient, usually after selection for cells that have incorporated the vector. Ex vivo cell transfection for diagnostics, research, or for gene therapy (e.g., via re-infusion of the transfected cells into the host organism) is well known to those of skill in the art. In certain embodiments, cells are isolated from the subject organism, transfected with a nucleic acid (gene or cDNA), and re-infused back into the subject organism (e.g., patient). Various cell types suitable for ex vivo transfection are well known to those of skill in the art. In ex vivo transfection, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including, but not limited to, transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells and may be used in accordance with the disclosure, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny. The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art. Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include, but are not limited to, epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular, hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc. In certain embodiments, the cell used for gene therapy is autologous to the patient. In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding APRIL-variants are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for a therapeutic effect. In a specific embodiment, stem or progenitor cells (e.g., myoblasts) are used. In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the APRIL-variant coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.
It is to be understood that although particular embodiments, specific configurations as well as materials and/or molecules, have been discussed herein for cells and methods according to the disclosure, various changes or modifications in form and detail may be made without departing from the scope and spirit hereof. The following examples are provided to better illustrate particular embodiments, and they should not be considered limiting the application.
The X-ray crystal structures of murine APRIL, in complex with human TACI or human BCMA,(21) were used as templates for designing receptor-selective variants of human APRIL. The ECD of murine APRIL shares 85% sequence identity with the human form. In addition, neither sequence contains an insertion or deletion relative to the other (
As human WT-APRIL does not express efficiently as a soluble recombinant protein in Escherichia coli and is difficult to purify with high yield from mammalian cell cultures, it was decided to test FLAG-tagged APRIL variants directly from conditioned culture medium of transfected HEK-293T cells. This is a validated approach that has been used previously.(14, 32) Protein expression was quantified by Western blot using an anti-FLAG tag antibody (
APRIL variants were tested using a receptor-binding ELISA as an initial screening assay to examine the real in vitro TACI and BCMA receptor binding and to determine receptor selectivity. Since we were interested in the relative changes in affinity of the APRIL variants for the TACI and BCMA receptors, we did not correct at this point for the different expression levels of the selected mutants. Thus, in the following experiments, although binding to the target receptor could seem weaker than for the WT variant, this is not necessarily the case (see below). Variants were grouped according to their predicted binding properties (i.e., being either TACI- or BCMA-specific,
In order to study receptor selectivity of APRIL variants in a standardized cell-based assay, BCMA:Fas- and TACI:Fas-expressing Jurkat cells were used as a reporter system.(28) In this assay, binding of APRIL to chimeric receptors triggers the pro-apoptotic Fas signaling pathway, leading to cell death. Reporter cells indeed expressed their respective chimeric receptors on the surface, as shown by FACS staining (
In order to test whether the R206E variant would also be unable to stimulate endogenous WT TACI, we used a receptor internalization assay.(32) We chose the mouse A20 cell line that has been shown to express high amounts of TACI.(10, 32) Treatment with WT-APRIL for 90 minutes at 37° C. triggered TACI internalization, as shown by the high-PE signal retained after acid treatment, which marks the antibody that was internalized, together with the receptor (
APRIL variants were tested for their activity on freshly isolated mouse B220+ splenocytes, which are known to respond to APRIL by increasing survival and IgA production.(14, 32) WT APRIL increased the number of live murine B cells remaining after six days of culture by a factor of 2 (
X-ray crystal structures of the extracellular domain (ECD) of murine APRIL in complex with the ECD of human TACI (PDB 1xu1) and the ECD of human BCMA (PDB 1xu2) have been solved at a resolution of 1.9 Å and 2.35 Å, respectively.(21) Computational design of receptor selective mutants was performed as described previously.(22, 23, 26) In short, amino acid residues with Van der Waals clashes, bad torsion angles or with a high energy in the crystal structure, were repaired by replacing the side chain conformations (rotamers) observed in the x-ray structure by lower energy rotamers; hydrogen bond networks were optimized using the Repair PDB option of the FoldX protein design algorithm.(19, 27) Next, a model of human APRIL in complex with human TACI and human BCMA was constructed by FoldX in silico mutagenesis of each of the non-conserved murine residues to its homologous human counterpart. Each residue in the receptor binding interface of human APRIL was subsequently mutated by FoldX to all other 19 naturally occurring amino acids using the BuildModel function. The effect on the interaction energy with TACI and BCMA was calculated as the difference in interaction energy (ΔΔG; in kcal/mol) between the interaction energy of the mutant and the wild-type amino acid, using the AnalyseComplex option. Amino acid substitutions were selected that: 1) caused a decrease in interaction energy toward one of the receptors or 2) caused an increase in interaction energy toward one receptor, while causing either a decrease in interaction energy or showing a neutral effect toward the other receptor or 3) caused an increase in interaction energy for both receptors but showing a different magnitude in change for one receptor over the other. Because some variants (mainly from the D132 series) showed severe intra-chain Van der Waals clashes upon mutation, it was decided to report the average interaction energy corrected for intra-chain Van der Waals clashes. This corrected interaction energy was calculated by summing the average interaction energy and the average ΔΔGintraclash energy, where ΔΔGintraclash is the difference in intra-chain clash energy (ΔΔGintraclash; in kcal/mol) between the intra-chain clash energy of the mutant and the wild-type amino acid. The reported corrected interaction energy was capped at +4 kcal/mol.
Flag-tagged APRIL variants selective for a receptor were generated using a Quick Change site-directed mutagenesis kit (Agilent Technologies, Santa Clara, USA) according to the manufacturer's guidelines, using the primers listed in Table 3. A pcDNA3.1 construct containing FLAG-tagged wild-type soluble APRIL (amino acid 105 to 250, numbering according to UniprotKB/Swiss-Prot 075888) was used as the PCR template and was described previously.(14) Plasmid DNA of clones was isolated (BIOKÉ, Leiden, The Netherlands) and presence of the mutation(s) was verified by DNA sequencing. Positive clones were selected and grown up for large-scale plasmid DNA isolation and used for subsequent transfections.
Human Jurkat and Raji cells and mouse A20 cells were cultured in RPMI-1640 (Gibco Life Technologies, Breda, NL). Primary mouse B cells were cultured in RPMI-1640 supplemented with 50 μM of 2-mercaptoethanol. 293T cells were cultured in Iscove's Modified Dulbecco Media (IMDM). All media were supplemented with 8% FCS, 2 mM L-glutamine, 40 μg/m1 penicillin and 40 U/ml streptomycin and maintained at 37° C. with 5% CO2.
To test the expression of the individual Flag-tagged APRIL variants, 293T cells were grown to 60% confluence in a six-well plate and transfected with the different variants using calcium phosphate precipitation. Following transfection, the cells were kept in culture for 72 hours before supernatant containing the soluble mutants was harvested and stored at −20° C. Expression of each of the APRIL mutants was then tested by Western blotting and the relative concentrations assessed. Briefly, supernatants were resolved on a 15% polyacrylamide gel, transferred to a nitrocellulose membrane and blocked overnight using Odyssey blocking buffer (LiCor Biosciences, Cambridge, United Kingdom) diluted 1:1 with PBS. The membrane was then incubated with mouse anti-FLAG-M2 (Sigma-Aldrich, Zwijndrecht, The Netherlands) at a concentration of 1 in 5000 diluted in PBS/0.2% TWEEN®20; the secondary antibody used was IRD800-coupled anti-mouse IgG1 (Westburg, Leusden, The Netherlands) diluted in PBS/0.2% TWEEN®20 and 0.02% SDS. Blots were visualized using a near-infrared imaging system (Odyssey, LiCor) according to the manufacturer's instructions, which allows quantification of bands to give a relative estimate of protein concentration.
The relative binding of the variants to either BCMA or TACI, was tested using a binding ELISA. The following proteins were used: human BCMA-Fc, human TACI-Fc (both generated in-house), mouse BCMA-Fc (R&D Systems, Abingdon, UK), mouse TACI-Fc (R&D Systems); in all cases the Fc portion is from human IgG1. BCMA-Fc and TACI-Fc were coated on 96-well Nunc Maxisorp plates (Thermo Fischer Scientific, Roskilde, Denmark) at concentrations of 1 μg/ml and 2 μg/ml, respectively, in 0.5 M sodium bicarbonate buffer pH 9.5, overnight at 4° C. Plates were then blocked with 5% BSA for one hour at 37° C. Soluble APRIL variants in the form of tissue culture conditioned medium were then added to the plate for two hours at 37° C. Following APRIL binding, plates were washed three times with PBS, 0.05% TWEEN®20. Bound APRIL was detected with 1 μg/ml of HRP-coupled anti-FLAG M2 and visualized with 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS) (Sigma-Aldrich). The absorbance was read at 405 nm using a UV-VIS microplate reader (BioRad, Veenendaal, The Netherlands).
In order to further assess the binding properties of the mutants and to measure apparent affinities and kinetics of receptor binding, a Surface Plasmon Resonance based receptor binding assay was performed on a Biacore 2000 (GE Healthcare, Diegem, Belgium). Anti-FLAG-M2 monoclonal antibody (Sigma-Aldrich) was diluted at a concentration of 5 μg/ml in 10 mM sodium acetate pH 4.5 and covalently immobilized (approx 1500 RU) to a CM-5 sensor chip (GE Healthcare), using standard amine coupling chemistry according to manufacturer's guidelines (Amine coupling kit, GE Healthcare). The different FLAG-APRIL variants in the form of tissue culture supernatants were captured onto the chip via the FLAG-tag at 10 μl/minute for five minutes, giving capture levels ranging from 159 to 207 RU. As a reference lane, one of the flow cells was left free of soluble FLAG-APRIL, to control for any background binding. BCMA- or TACI-Fc were then injected for three minutes over all four flow cells at 30 μl/minutes at increasing concentrations (ranging from 1-50 nM) using the single cycle kinetics method at 25° C. Dissociation was monitored for five minutes. The resulting curves were fitted using a 1:1 Langmuir model using BIAevaluation software 4.1. For each combination of FLAG-APRIL and BCMA- or TACI-Fc, the apparent ka, kd and KD were calculated from a global fit of binding curves from at least three separate experiments. Non-specific binding in the reference cell was subtracted before curve fitting. Regeneration of the anti-FLAG antibody surface was carried out with a 10-minute injection at 30 μl/minute of a mixture of ⅓ volume of TBS pH 11.5, ⅓ volume of Ionic solution and ⅓ volume of water. The Ionic solution was comprised of KSCN (0.46 M), MgCl2 (1.83 M), urea (0.92 M) and guanidine-HCl (1.83 M).
Jurkat-BCMA:Fas-2309 cl13 reporter cells were generated as described.(28) TACI:Fas Jurkat cells reporter cell lines were generated essentially as described previously for EDAR:Fas cells.(29) 293T cells were transiently transfected with pMSCVpuro-TACI:Fas and co-transfected with the pHIT60 and VSV-G plasmids, containing the sequences for gag-pol and VSV-G, respectively. pMSCVpuro-TACI:Fas encodes the haemaglutinin signal peptide (amino acid sequence MAIIYLILLFTAVRG), part of the extracellular domain of human TACI (amino acids 2-118), amino acids VD and the transmembrane and intracellular domains of human Fas (amino acids 169-335). After transfection, 293T cells were incubated for 48 hours in RPMI supplemented with 10% FCS. Six ml of virus-containing 293T cell supernatants supplemented with 8 μg/ml of polybrene were added to 106 Fas-deficient Jurkat-JOM2 cells (a kind gift of Olivier Micheau, University of Dijon, France) in two times 3 ml additions for 3 and 16 hours, respectively, after which time, cells were cultured in RPMI 10% for 72 hours and then selected with 0.5 μg/ml of puromycin and cloned. Clones were screened for their selective sensitivity to Fc-BAFF but not Fc-EDA1(30) and one clone (clone 112) was selected for further experimentation. For the killing assay, 3×104 Jurkat cells were seeded per well in a 96-well plate and stimulated with doubling dilutions of quantity-matched supernatants for a period of 16 hours. Cells were subsequently harvested, spun down and re-suspended in 250 μl of Nicoletti Buffer containing 50 μg/ml of propidium iodide and stored for at least 24 hours at 4° C. (as described in reference (31)). Analysis of apoptosis was assessed by flow cytometric measurement of PI stained nuclei using a FACScalibur system (Becton Dickinson, San Jose, Calif., USA).
To determine receptor internalization, 5×105 cells were labeled with phycoerythrin (PE)-conjugated anti-human or anti-mouse TACI antibodies (Clones: 1A1-K21-M22 and 8F10, respectively, BD Biosciences, Breda, The Netherlands) and incubated with conditioned medium containing matched amounts of APRIL variants for a period of 90 minutes at 37° C. (the optimal time point was determined in a time-course experiment). Following incubation, cells were cooled on ice to halt endocytosis, treated for one minute with either acid solution (0.154 M NaCl pH 2, to strip off surface-exposed antibody) or PBS, 1% BSA as a control and then analyzed by FACS for the presence of the remaining PE-label. The efficacy of the acid stripping was tested and optimized previously.(32) All APRIL receptor staining on lymphoma cells (mouse and human) were performed after incubation with FcR blocking reagent (Miltenyi Biotech, Leiden, The Netherlands). TACI internalization was also studied using confocal microscopy. Cells were stained with PE-conjugated anti-mouse TACI antibody, incubated with APRIL in conditioned medium (as described above for FACS analysis), re-suspended in mounting medium (VectaShield, Brunschwig Chemie, Amsterdam, NL) and transferred onto a glass slide. Cells were kept on ice before microscopy.
B cells were purified from murine splenocytes using magnetic activated cell separation (MACS) with CD45R/B220 MACS beads (Miltenyi Biotec, Utrecht, The Netherlands). Purified B cells were then seeded in 96-well round-bottomed microtiter plates at a density of 2×105 cells/well, and incubated with diluted conditioned media containing the APRIL variants. After six days of incubation, viability was assessed using PI exclusion and supernatants were assayed for IgA by ELISA. Coated 96-well plates (2 μg/ml anti-mouse Ig, Southern Biotech) were blocked with PBS, 5% BSA and, following washes with PBS, 0.05% TWEEN®20, incubated at 37° C. for one hour with the collected supernatants. Bound IgA were detected with HRP-labeled anti-mouse-IgA (Southern Biotech) and ABTS (Sigma-Aldrich).
This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application Ser. No. 61/739,941, filed Dec. 20, 2012, the disclosure of which is hereby incorporated herein in its entirety by this reference.
| Number | Date | Country | |
|---|---|---|---|
| 61739941 | Dec 2012 | US |
